New and emerging lipid-modifying drugs to lower LDL cholesterol
Cardiovascular disease (CVD) represents the leading cause of death worldwide. The role of low-density lipoprotein-cholesterol (LDL-C) in the pathophysiology of atherosclerosis and CVD has been well recognized. Statins are the standard of care for the management of hypercholesterolaemia, and their ef...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
BioExcel Publishing Ltd,
2021-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_9426d6a0cee648a68cecf03c0b5f923c | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Constantine E Kosmas |e author |
| 700 | 1 | 0 | |a Dafni Pantou |e author |
| 700 | 1 | 0 | |a Andreas Sourlas |e author |
| 700 | 1 | 0 | |a Evangelia J Papakonstantinou |e author |
| 700 | 1 | 0 | |a Rogers Echavarria Uceta |e author |
| 700 | 1 | 0 | |a Eliscer Guzman |e author |
| 245 | 0 | 0 | |a New and emerging lipid-modifying drugs to lower LDL cholesterol |
| 260 | |b BioExcel Publishing Ltd, |c 2021-10-01T00:00:00Z. | ||
| 500 | |a 10.7573/dic.2021-8-3 | ||
| 500 | |a 1740-4398 | ||
| 520 | |a Cardiovascular disease (CVD) represents the leading cause of death worldwide. The role of low-density lipoprotein-cholesterol (LDL-C) in the pathophysiology of atherosclerosis and CVD has been well recognized. Statins are the standard of care for the management of hypercholesterolaemia, and their effectiveness in lowering LDL-C and reducing CVD risk in both primary and secondary prevention has been well established. However, several patients fail to attain optimal LDL-C goals or are intolerant to statins, especially at high doses. PCSK9 inhibitors, bempedoic acid, inclisiran, ANGPTL3 inhibitors, PPARβ/δ agonists and LXR agonists are novel or upcoming LDL-C-lowering agents that have shown promising beneficial results. This review aims to present and discuss the current clinical and scientific data pertaining to the new and emerging lipid-modifying LDL-C-lowering drugs. | ||
| 546 | |a EN | ||
| 690 | |a angptl3 inhibitors | ||
| 690 | |a bempedoic acid | ||
| 690 | |a cardiovascular disease | ||
| 690 | |a inclisiran | ||
| 690 | |a ldl-c-lowering | ||
| 690 | |a lxr agonists | ||
| 690 | |a pcsk9 inhibitors | ||
| 690 | |a pparβ/δ agonists | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Drugs in Context, Pp 1-22 (2021) | |
| 787 | 0 | |n https://www.drugsincontext.com/new-and-emerging-lipid-modifying-drugs-to-lower-ldl-cholesterol | |
| 787 | 0 | |n https://doaj.org/toc/1740-4398 | |
| 856 | 4 | 1 | |u https://doaj.org/article/9426d6a0cee648a68cecf03c0b5f923c |z Connect to this object online. |